Claim 1: the use of a composition comprising a population of postpartum derived cells in the treatment of a degenerative Eye condition or to decrease the loss of CellsThe degeneration of photoreceptor in the retina, where the postpartum derived cells were isolated from Human umbilical cord Tissue substantially free of Blood,And where the population of postpartum derived cells modulates Integrin Receptors and phagocytic avb5 CD36.Claim 2: the use according to claim 1, wherein the Bridge of postpartum derived cells secrete molecules selected from mfg-e8, Gas6,Thrombospondin (TSP) - TSP - 1 and 2, and where the Bridge molecules bind to Integrin Receptors and phagocytic avb5 CD36.Claim 3: Use according to claim 1,Where the population of cells isolated from Human umbilical cord Tissue substantially free of Blood has the ability to expand in CultureHas the potential to differentiate into cells of at least a neural phenotype.Retain a normal karyotype after Passes and has the following characteristics: (a) potential for duplication of 40 people in cultivation； (b) production of CD10, CD13, CD44,CD73 and CD90； (c) lack of production of CD31, CD45, CD34, CD117, and cd141,And (d) increased expression of genes encoding Interleukin 8 and reticul u00f3n 1 with regard to a cell that is a Human FibroblastA cell or a mesenchymal stem cell of bone marrow of the iliac Crest.Reivindicación 1: El uso de una composición que comprende una población de células derivadas del posparto en el tratamiento de una afección ocular degenerativa o la reducción de la pérdida de células fotorreceptoras en la degeneración de la retina, en donde las células derivadas del posparto se aíslan del tejido del cordón umbilical humano sustancialmente libre de sangre, y en donde la población de células derivadas del posparto modula los receptores fagocíticos integrina avb5 y CD36. Reivindicación 2: El uso de acuerdo con la reivindicación 1, en donde las células derivadas del posparto secretan moléculas puente s
